| Name | Title | Contact Details |
|---|---|---|
Mike Tomasco |
Senior Vice President - Chief Information Officer | Profile |
Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena’s development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company’s pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax™ (nelipepimut-S) and GALE-301. NeuVax is currently in a pivotal, Phase 3 clinical trial with several concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancers and in a Phase 1b given sequentially with GALE-302.
Our vision is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and novel computational platform to accelerate drug discovery.
AltruBio is developing first-in-class immune-modulators targeting diseases of #immunology and #inflammation. Its world-class global team brings a breadth of expertise in immunology and drug development that will help advance their biologic treatments to patients.
miR’s Disease Management Platform™ gives providers and patients first-time access to actionable health data, illuminating a clear path to cancer management.
Tgs Technologies, Llc is a Cranberry Twp, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.